好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying Multiple Sclerosis Relapses from Clinical Notes Using Combined Rule-based and Deep Learning Methodologies
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
3-001

To develop an algorithm to extract multiple sclerosis (MS) relapse events from clinical notes from the 好色先生 Axon Registry, a neurology-specific patient registry that uses real-world electronic health record (EHR) data. 

Relapse frequency is a key outcome measure for MS patients, indicating disease activity. MS relapses are often documented in unstructured clinical notes rather than structured fields in the EHR, and mechanisms to automatically extract this information will better enable real-world evidence (RWE) studies.

As of May 2022, 46,600 MS patients were identified using structured ICD codes and mention of MS in clinical notes from 3.2 million patients and their 24 million patient visits in the Axon Registry. A combined rule-based, deep learning (DL) approach was developed to classify, at a given encounter, the relapse status (current relapse, no relapse, discussion of past relapse only, or unknown) of these patients.

A thousand notes were randomly sampled from MS patient notes containing relapse phrases, identified via string searches. These notes were labeled by a clinical expert for their relapse statuses to generate training, validation, and testing sets (70-15-15 split). Using the training and validation sets, a DL model was trained to classify notes into one of the relapse statuses. Performance was assessed on the test set.


The model had an overall accuracy of 0.88. For current relapse status, a sensitivity of 0.83 and specificity of 0.97 were achieved.

Identified MS patients averaged 0.58+/-0.55 relapses/year and the proportion of patients with relapses decreased over time (2014: 14.74% vs. 2021: 9.86%), consistent with clinical expectations.


We used a combined rule-based, DL methodology to extract relapses from clinical notes. Performance metrics and clinically consistent patterns found in the results provide confidence to support using this scalable algorithm for RWE studies.

Authors/Disclosures
Iris Chin, PhD (Verana Health)
PRESENTER
Dr. Chin has received personal compensation for serving as an employee of Verana Health.
Heather Moss, MD, PhD, FAAN (Spencer Center for Vision Research at Stanford) Dr. Moss has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Verana Health. Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms. The institution of Dr. Moss has received research support from NIH. The institution of Dr. Moss has received research support from Research to Prevent Blindness. Dr. Moss has received intellectual property interests from a discovery or technology relating to health care. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with National Institutes of Health. Dr. Moss has a non-compensated relationship as a Board of Directors with North American Neuro-ophthalmology Society that is relevant to AAN interests or activities.
Kathryn Sands (Verana Health) No disclosure on file
No disclosure on file
No disclosure on file
Aracelis Torres (Verana Health) No disclosure on file